{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:49:01Z","timestamp":1787028541815,"version":"build-2736575974"},"reference-count":74,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:00:00Z","timestamp":1717891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Since transcription factor Forkhead Box P3 (FoxP3) was identified as a specific regulatory T cell (Treg) marker, researchers have scrutinized its value as a potential novel therapeutic target or a prognostic factor in various types of cancer with inconsistent results. The present analysis was performed to assess the influence of Treg FoxP3 expression on the prognosis of primary melanoma and to evaluate the correlations with various clinicopathological prognostic factors. We analyzed all eligible patients with stage pT3 primary malignant melanomas treated in a tertiary cancer center. Immunohistochemical staining for Treg FoxP3 expression was performed on retrospectively identified paraffin blocks and subsequently correlated with the outcomes of the patients. A total of 81% of the patients presented a positive Treg FoxP3 expression, being correlated with a higher risk of lymph node metastasis, tumor relapse, and death. Moreover, positive expression was statistically associated with a shorter OS. The tumor relapse rate was estimated at 36.7%. A positive expression of Treg FoxP3 and lymph node metastasis were associated with a higher risk of death based on multivariate analysis. Treg FoxP3 expression may be used as an independent prognostic factor in patients with malignant melanoma to evaluate tumor progression and survival.<\/jats:p>","DOI":"10.3390\/ijms25126377","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T10:08:43Z","timestamp":1718014123000},"page":"6377","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Expression of Forkhead Box P3 T Regulatory Lymphocytes as a Prognostic Factor in Malignant Melanomas"],"prefix":"10.3390","volume":"25","author":[{"given":"Vlad Alexandru","family":"G\u00e2ta","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology and Gynecologic Oncology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"\u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0726-6381","authenticated-orcid":false,"given":"Andrei","family":"Pa\u0219ca","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and Gynecologic Oncology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"\u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-5325","authenticated-orcid":false,"given":"Andrei","family":"Roman","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"},{"name":"Department of Radiology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian Vlad","family":"Muntean","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"},{"name":"Department of Plastic and Reconstructive Surgery, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drago\u0219 \u0218tefan","family":"Morariu","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Ion Chiricu\u021b\u0103\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-0906","authenticated-orcid":false,"given":"Eduard Alexandru","family":"Bonci","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and Gynecologic Oncology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"\u201cChampalimaud\u201c Research and Clinical Centre, 1400-038 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2298-6361","authenticated-orcid":false,"given":"Constantin","family":"Dina","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Ovidius University, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8535-9677","authenticated-orcid":false,"given":"Loredana","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Dermatology, Emergency County Hospital Cluj-Napoca, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,9]]},"reference":[{"key":"ref_1","unstructured":"(2024, May 26). National Cancer Institute (NIH), Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Melanoma of the Skin 2020, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/jayao.2016.0074","article-title":"Small Numbers, Big Challenges: Adolescent and Young Adult Cancer Incidence and Survival in New Zealand","volume":"6","author":"Ballantine","year":"2017","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ypmed.2016.08.032","article-title":"Melanoma burden and recent trends among non-Hispanic whites aged 15\u201349, United States","volume":"91","author":"Watson","year":"2016","journal-title":"Prev. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jaad.2016.09.029","article-title":"The potential impact of reducing indoor tanning on melanoma prevention and treatment costs in the United States: An economic analysis","volume":"76","author":"Guy","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14737140.2016.1211936","article-title":"Ipilimumab in melanoma","volume":"16","author":"Specenier","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","article-title":"Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than two years following treatment in a phase III trial (MDX010-20)","volume":"24","author":"McDermott","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2018.11.002","article-title":"Advanced stage melanoma therapies: Detailing the present and exploring the future","volume":"133","author":"Luther","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomized, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomized, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): An open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_12","first-page":"1287","article-title":"Effectiveness and safety profile of ipilimumab therapy in previously treated patients with unresectable or metastatic melanoma\u2014The Romanian Patient Access Program","volume":"22","author":"Ciuleanu","year":"2017","journal-title":"J. BUON"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to PD1\/PDL1 checkpoint inhibition","volume":"52","author":"Long","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2326s","DOI":"10.1158\/1078-0432.CCR-05-2517","article-title":"Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment","volume":"12","author":"Gajewski","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/14737159.2014.928206","article-title":"Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment","volume":"14","author":"Camisaschi","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"viii10","DOI":"10.1093\/annonc\/mds257","article-title":"Melanoma as a model tumour for immuno-oncology","volume":"23","author":"Maio","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1758835919848872","DOI":"10.1177\/1758835919848872","article-title":"Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?","volume":"11","author":"Incorvaia","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.18632\/oncotarget.23989","article-title":"Genetic alterations in main candidate genes during melanoma progression","volume":"9","author":"Sini","year":"2018","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12659\/MSM.905862","article-title":"Regression and Sentinel Lymph Node Status in Melanoma Progression","volume":"24","author":"Letca","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","article-title":"Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study","volume":"31","author":"Thomas","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_28","first-page":"592","article-title":"Tumor infiltrating lymphocytes as a prognostic factor in malignant melanoma. Review of the literature","volume":"22","author":"Gata","year":"2017","journal-title":"J. BUON"},{"key":"ref_29","first-page":"2700","article-title":"The value of tumor infiltrating lymphocytes as prognostic factor for lymph node status and survival amongst patients with cutaneous malignant melanoma","volume":"25","author":"Buiga","year":"2020","journal-title":"J. BUON"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pathol.2015.12.006","article-title":"Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy","volume":"48","author":"Lee","year":"2016","journal-title":"Pathology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/1078-0432.CCR-11-3216","article-title":"The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: A critical review of the literature","volume":"18","author":"deLeeuw","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI74894","article-title":"Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis","volume":"125","author":"Reissfelder","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"dju435","DOI":"10.1093\/jnci\/dju435","article-title":"Objective measurement and clinical significance of TILs in non-small cell lung cancer","volume":"107","author":"Schalper","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T Cells and Human Disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ni.3466","article-title":"Immunometabolism of regulatory T cells","volume":"17","author":"Newton","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2016.07.006","article-title":"Memory of Inflammation in Regulatory T Cells","volume":"166","author":"Gonzalez","year":"2016","journal-title":"Cell"},{"key":"ref_37","first-page":"723","article-title":"Cell interactions in the induction of tolerance: The role of thymic lymphocytes","volume":"18","author":"Gershon","year":"1970","journal-title":"Immunology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4049\/jimmunol.108.3.586","article-title":"Suppressor T cells","volume":"108","author":"Gershon","year":"1972","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-3083.1988.tb02344.x","article-title":"Do suppressor T cells exist?","volume":"27","year":"1988","journal-title":"Scand. J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1002\/eji.200737593","article-title":"Regulatory T cells\u2014A brief history and perspective","volume":"37","author":"Sakaguchi","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cei.13290","article-title":"Mechanisms of human FoxP3(+) T(reg) cell development and function in health and disease","volume":"197","author":"Attias","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/PAT.0000000000000314","article-title":"FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor","volume":"47","author":"Leslie","year":"2015","journal-title":"Pathology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1593806","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: A systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.18632\/oncotarget.1600","article-title":"FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis","volume":"5","author":"Tan","year":"2014","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1755-148X.2011.00879.x","article-title":"FoxP3 expression on melanoma cells is related to early visceral spreading in melanoma patients treated by electrochemotherapy","volume":"24","author":"Quaglino","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0625.2011.01260.x","article-title":"Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma","volume":"20","author":"Knol","year":"2011","journal-title":"Exp. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: A systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.12641","article-title":"High expression of FOXP3 in primary melanoma is associated with tumour progression","volume":"170","author":"Gerber","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3389\/fimmu.2019.02486","article-title":"Foxp3 Post-translational Modifications and Treg Suppressive Activity","volume":"10","author":"Deng","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.coi.2011.07.012","article-title":"Distinct regulatory CD4+ T cell subsets; differences between na\u00efve and antigen specific T regulatory cells","volume":"23","author":"Hall","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ni.1760","article-title":"Foxp3+ regulatory T cells: Differentiation, specification, subphenotypes","volume":"10","author":"Feuerer","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.4049\/jimmunol.1402695","article-title":"Regulatory T Cells in Melanoma Revisited by a Computational Clustering of FOXP3+ T Cell Subpopulations","volume":"196","author":"Fujii","year":"2016","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.immuni.2017.06.015","article-title":"Identification of Natural Regulatory T Cell Epitopes Reveals Convergence on a Dominant Autoantigen","volume":"47","author":"Leonard","year":"2017","journal-title":"Immunity"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/s41590-019-0429-7","article-title":"Connecting blood and intratumoral T(reg) cell activity in predicting future relapse in breast cancer","volume":"20","author":"Wang","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/jmedgenet-2012-100759","article-title":"The immunogenetics of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome","volume":"49","author":"Torgerson","year":"2012","journal-title":"J. Med. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri.2017.75","article-title":"The regulation of immune tolerance by FOXP3","volume":"17","author":"Lu","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jcyt.2018.01.011","article-title":"Regulatory perspective on in vitro potency assays for human T cells used in antitumor immunotherapy","volume":"20","author":"Hoefnagel","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_60","first-page":"276","article-title":"Th1 polarization and apoptosis-inducing activity of CD4+ T -cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo","volume":"21","author":"Yu","year":"2006","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/labinvest.3700389","article-title":"Tumor-infiltrating T lymphocytes: Friends or foes?","volume":"86","author":"Yu","year":"2006","journal-title":"Lab. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1073\/pnas.0801003105","article-title":"IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis","volume":"105","author":"Oh","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00262-011-1025-3","article-title":"Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction","volume":"60","author":"Niu","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.3748\/wjg.v16.i43.5502","article-title":"FOXP3 expression and clinical characteristics of hepatocellular carcinoma","volume":"16","author":"Wang","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1464-410X.2010.10020.x","article-title":"FOXP3 and survival in urinary bladder cancer","volume":"108","author":"Winerdal","year":"2011","journal-title":"BJU Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6061\/clinics\/2012(05)13","article-title":"Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas","volume":"67","author":"Cunha","year":"2012","journal-title":"Clinics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.leukres.2010.09.008","article-title":"No mutation in the FOXP3 gene in acute leukemias","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-012-1348-8","article-title":"Up-regulation of Foxp3 participates in progression of cervical cancer","volume":"62","author":"Zeng","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1365-2133.2010.10199.x","article-title":"Perturbations of both non-regulatory and regulatory FOXP3+ T cells in patients with malignant melanoma","volume":"164","author":"Fujii","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.amjoto.2014.08.009","article-title":"FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients","volume":"35","author":"Ryan","year":"2014","journal-title":"Am. J. Otolaryngol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.humpath.2017.12.022","article-title":"Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas","volume":"73","author":"Selim","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Varghese, F., Bukhari, A.B., Malhotra, R., and De, A. (2014). IHC Profiler: An open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096801"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/12\/6377\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:56:05Z","timestamp":1760108165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/12\/6377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,9]]},"references-count":74,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25126377"],"URL":"https:\/\/doi.org\/10.3390\/ijms25126377","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,9]]}}}